Click Therapeutics

Yesterday, at DTx West, the pharma giant and the DTx company sat down to discuss implementing DTx for mental illness.

The randomized controlled trial of the jointly-developed digital therapeutics will be conducted using Verily's Project Baseline and enroll up to 540 patients. 

MobiHealthNews spoke with Pear Therapeutics, Click Therapeutics and DTx newcomer Mahana Therapeutics to discuss whether in-licensing is the way to go for those just entering the space.

Efficient distribution, dissipating stigma and an emphasis on decentralized trials are all working in favor of digital treatments, according to a panel of digital therapeutics executives and industry stakeholders.

The companies will be collaborating on a prescription digital therapeutic for patients with schizophrenia built on Click Therapeutics' tech platform.

Otsuka intends to invest more than $300 million in an FDA-cleared software app that will apply cognitive therapy principals either with or without prescription drugs. 

Behavioral health technology provider AbleTo has announced Trip Hofer as its new CEO.

This morning, prescription digital therapeutic developer Click Therapeutics closed a $17 million funding round led by Sanofi Ventures, a subsidiary of pharma giant Sanofi.

The past month has seen a succession of publications offering support for Click Therapeutics’ digital offering for patients with major depressive disorder (MDD).